Navigation Links
Cardioxyl Pharmaceuticals Raises $28 Million In Series B Financing Led By OrbiMed Advisors
Date:11/13/2012

CHAPEL HILL, N.C., Nov. 13, 2012 /PRNewswire/ -- Cardioxyl Pharmaceuticals, Inc. announced today that it has raised $28 million in a Series B financing led by OrbiMed Advisors.  New investor Osage University Partners joined OrbiMed and returning investors New Enterprise Associates (NEA) and The Aurora Funds in the financing. Proceeds from this latest round will be used to further advance Cardioxyl's second-generation nitroxyl (HNO) donor programs for the treatment of acute and chronic heart failure.  In conjunction with OrbiMed's role as lead investor in this funding round, OrbiMed Venture Partners Peter Thompson, M.D., and Anthony G. Johnson, M.D., have joined the Cardioxyl Board of Directors.  Bill Harrington, M.D., led the financing for Osage University Partners.

"OrbiMed has a strong track record of identifying innovative and successful companies within the healthcare industry. The firm's commitment, along with that of Osage, NEA and Aurora, creates an outstanding investor syndicate," said Chris Kroeger, M.D., President and Chief Executive Officer of Cardioxyl. "We are also very pleased to welcome Peter Thompson and Tony Johnson to the Cardioxyl Board. Their extensive drug development and leadership experience in the pharmaceutical industry will be invaluable as we advance HNO drug candidates to help improve the health and quality of life for patients with heart failure."

Peter Thompson, M.D., is a Venture Partner with OrbiMed with over 20 years of industry experience. He co-founded and was CEO of Trubion Pharmaceuticals; co-founded Cleave BioSciences; serves on the Boards of Cleave, Anthera, Methylgene, Principia Biosciences, and Response Biomedical; and previously served as an executive of Chiron Corporation and Becton Dickinson. Dr. Thompson is an Ernst & Young Entrepreneur of the Year awardee, an Affiliate Professor of Neurosurgery at the University of Washington, an inventor on numerous patents, and a board-certified internist and oncologist. He was on staff at the National Cancer Institute following his internal medicine training at Yale University.

"Cardioxyl's HNO donor programs represent a unique and highly differentiated approach to treating heart failure, with a significant body of human clinical experience," said Dr. Thompson. "I look forward to joining the Cardioxyl Board and helping to advance this novel therapy for a devastating disease that has seen little innovation in clinical practice over the past decade."

Anthony G. Johnson, M.D., M.P.H., M.B.B.S., F.R.A.C.P., is also an OrbiMed Venture Partner with more than 20 years of pharmaceutical industry leadership experience. Dr. Johnson led exploratory clinical development as Vice President, Discovery Medicine Clinical Pharmacology at Bristol-Myers Squibb and was on the executive team of a Center of Excellence for Drug Discovery responsible for multiple therapeutic areas at GlaxoSmithKline. He established the James Lance GlaxoWelcome Medicines Research Unit and had a tenured academic appointment at Queensland University, where he completed extensive clinical research. He is a fellow of the Royal Australasian College of Physicians, and is board certified in internal medicine, geriatric medicine, and clinical pharmacology with 18 years of broad clinical experience.

"Cardioxyl has an exciting opportunity to impact heart failure, a disease with a high degree of unmet medical need," said Dr. Johnson. "The pharmacological effects anticipated from an HNO donor, namely improved cardiac relaxation, combined with enhanced cardiac contractility and peripheral vasodilation, can address a broad spectrum of the physiologic abnormalities observed in this disorder."

About Cardioxyl Pharmaceuticals

Cardioxyl Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery and development of new classes of safe and effective therapeutic agents for the treatment of cardiovascular disease. Cardioxyl has developed industry-leading expertise in the chemistry, biology and clinical applications of nitroxyl (HNO) technology. The company's core HNO platform has generated several pre-clinical and clinical candidates. Cardioxyl is a privately held company financed by life science venture investors, including New Enterprise Associates, OrbiMed, Aurora Funds and Osage University Partners.


'/>"/>
SOURCE Cardioxyl Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... The global  anxiety disorders and depression treatment market  is ... incidence of depression worldwide is anticipated to drive the market growth in the ... demand for antidepressants in the recent years. Continue ... ... ...
(Date:1/23/2017)... 23 janvier 2017  ResMed (NYSE : RMD), BMC (Pékin, ... ont annoncé aujourd,hui qu,ils se sont mis d,accord sur ... les parties. BMC et 3B seront autorisés à vendre ... à ResMed, et ResMed effectuera le paiement de la ... le litige de Floride entre les deux parties. Le ...
(Date:1/23/2017)... DIEGO , 23. Januar 2017  ResMed (NYSE: ... ) und 3B Medical ( Winter Haven, ... auf eine Vereinbarung über die Beilegung aller globalen Rechtsstreitigkeiten ... der Verkauf ihrer bestehenden Produkte im Tausch ... einmalige Zahlung an 3B leisten, um das in ...
Breaking Medicine Technology:
(Date:1/23/2017)... ... ... “Crossing the Bar”: a moving and eloquent drama depicting the events ... is the creation of published author, Charlotte Hotte, a North Carolina native, a mother ... of the book to her sister, Denise, wishes to acknowledge her savior, Jesus Christ, ...
(Date:1/22/2017)... ... January 22, 2017 , ... Phytocéane invites clients to take an ... of the world with ZANZIBAR MILKY CREAM. Inspired by the beauty of Zanzibar, a ... Coconut Oil and moisturizing vegetal coral to create this gentle, velvety body cream to ...
(Date:1/21/2017)... ... 21, 2017 , ... Salveo for life, a company that distributes an effervescent ... United States as part of its presence to expand its market reach. , Using ... the productions of nasty toxins as a result of drinking alcohol, eliminating those toxins ...
(Date:1/21/2017)... CA (PRWEB) , ... January 21, 2017 , ... ... that Redwood Family Dermatology has recently joined their multi-specialty medical group. ... full range of cosmetic services. , “We’re excited to add this excellent dermatology ...
(Date:1/20/2017)... ... ... A new partnership between Goodwill® and Roadie, Inc. aims to make it ... to couches to dressers and bicycles. Roadie — the national on-the-way delivery network — ... center through February 28th. , “January is an exciting time when resolutions are ...
Breaking Medicine News(10 mins):